Jane S. Ricciuti, RPh, MS


June 10, 2003

In This Article


The Therapeutic Products Directorate (TPD) of Health Canada grants marketing authorization to manufacturers through a Notice of Compliance (NOC). This column contains an update on the most recently authorized NOCs.

This month's column reviews TPD new label indications for:

Anti-asthmatic agents

  • Advair Diskus (salmeterol)

  • Qvar (beclomethasone dipropionate)

Antidepressant agents

  • Effexor and Effexor XR (venlafaxine)

  • Sertraline (multiple manufacturers)

Antineoplastic agents

  • Photofrin (porfimer sodium)

  • Zoladex (goserelin acetate)

Antipsychotic agents

  • Zyprexa (olanzapine)

Antiviral agents

  • Valtrex (valacyclovir)

Anti-arthritis agents

  • Arava (leflunomide)

  • Vioxx (rofecoxib)


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.